- Home
- POAI vs ENVB Comparison
POAI vs ENVB Comparison
Compare POAI & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POAI
- ENVB
- Stock Information
- Founded
- POAI 2002
- ENVB 1994
- Country
- POAI United States
- ENVB United States
- Employees
- POAI N/A
- ENVB N/A
- Industry
- POAI Industrial Specialties
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- POAI Health Care
- ENVB Health Care
- Exchange
- POAI Nasdaq
- ENVB Nasdaq
- Market Cap
- POAI 4.9M
- ENVB 4.1M
- IPO Year
- POAI N/A
- ENVB N/A
- Fundamental
- Price
- POAI $1.21
- ENVB $0.35
- Analyst Decision
- POAI Hold
- ENVB Strong Buy
- Analyst Count
- POAI 1
- ENVB 1
- Target Price
- POAI N/A
- ENVB $10.00
- AVG Volume (30 Days)
- POAI 3.4M
- ENVB 1.0M
- Earning Date
- POAI 11-12-2024
- ENVB 11-14-2024
- Dividend Yield
- POAI N/A
- ENVB N/A
- EPS Growth
- POAI N/A
- ENVB N/A
- EPS
- POAI N/A
- ENVB N/A
- Revenue
- POAI $1,484,223.00
- ENVB N/A
- Revenue This Year
- POAI N/A
- ENVB N/A
- Revenue Next Year
- POAI $569.48
- ENVB N/A
- P/E Ratio
- POAI N/A
- ENVB N/A
- Revenue Growth
- POAI N/A
- ENVB N/A
- 52 Week Low
- POAI $0.55
- ENVB $0.30
- 52 Week High
- POAI $3.76
- ENVB $2.92
- Technical
- Relative Strength Index (RSI)
- POAI 54.24
- ENVB 46.61
- Support Level
- POAI $1.16
- ENVB $0.35
- Resistance Level
- POAI $1.42
- ENVB $0.39
- Average True Range (ATR)
- POAI 0.36
- ENVB 0.05
- MACD
- POAI -0.00
- ENVB -0.00
- Stochastic Oscillator
- POAI 19.21
- ENVB 19.56
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.